Table 2.

Impact of antimalarial drugs on development and persistence of P. falciparum gametocytes

Drug(s) a Median gametocyte prevalence (% [IQR]) on day 7 for those who were gametocyte free on day 0Median gametocyte prevalence (% [IQR]) for those who were gametocyte carriers on day 0 References
Day 7Day 14
Non-ACT drugs
    CQ35 (26–44)76 (67–88)60 (43–83) 4, 7, 127, 183, 333, 367, 383, 384, 440, 466
    SP55 (47–62)87.1 (78.3–97.5)71.4 (54.0–83.0) 7, 55, 93, 183, 287, 333, 367, 383, 440, 449, 466, 502
    AQ15 (8–23)69 (58–74)37 (22–46) 93, 440, 442, 456
    SP + CQ39 (38–44)89 (58–100)60 (33–74) 93, 183, 375, 461, 489
    SP + AQ10 (7–19)56 (33–78)33 (24–43) 55, 117, 144, 146, 287, 444, 454, 526, 530
ACT regimens
    SP + AS8 (5–18)38 (25–60)18 (17–75) 55, 185, 287, 412, 466, 504
    AQ + AS5 (0–13)35 (30–40)13 (0–41) 74, 103, 117, 146, 147, 185, 189, 339, 454, 526
    MQ + AS1 (1–3)13 (3–30)1 (0–9) 11, 12, 146, 169, 205, 242, 266, 437, 451, 489, 532
    AL2 (1–4)20 (18–41)16 (4–19) 55, 74, 117, 144, 146, 147, 205, 213, 242, 266, 279, 339, 353, 374, 444, 461, 489, 527, 530, 532
    DHA-PPQ4 (3–5)33 (15–49)23 (17–29) 11, 12, 169, 189, 213, 279, 374, 437, 527, 530, 532
ACT-PQ regimen
    SP + AS + PQ0 (0–0)20 (0–40)0 (0–0) 412, 506
  • a ACT, artemisinin combination therapy; CQ, chloroquine; SP, sulfadoxine-pyrimethamine; AQ, amodiaquine; AS, artesunate; MQ, mefloquine; AL, artemether-lumefantrine; DHA-PPQ, dihydroartemisinin-piperaquine; PQ, primaquine. Only drug combinations for which we were able to obtain raw data for two or more trials were included.